Snus use, smoking and survival among prostate cancer patients

International Journal of Cancer

Volumn 139, Issue 12, 2016, Pages 2753-2759

  Wilson, Kathryn M ^a,b   Markt, Sarah C ^a   Fang, Fang ^c   Nordenvall, Caroline ^c   Rider, Jennifer R ^a,d   Ye, Weimin ^c   Adami, Hans Olov ^a,c   Stattin, Pär ^e   Nyrén, Olof ^c   Mucci, Lorelei A ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e UMEÅ UNIVERSITY   (Sweden)

Author keywords

cancer survival; prostate cancer; smoking; snus; tobacco use

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BODY MASS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CAUSE OF DEATH; COHORT ANALYSIS; CONSTRUCTION WORKER; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; SMOKELESS TOBACCO; SMOKING; SWEDISH CITIZEN; ADVERSE EFFECTS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; REGISTER; SWEDEN; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; REGISTRIES; SMOKING; SWEDEN; TOBACCO, SMOKELESS;

EID: 84994140675     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30411     Document Type: Article

References (63)

1. Carter BD, Abnet CC, Feskanich D, et al. Smoking and mortality—beyond established causes. N Engl J Med 2015; 372:631–40.
2. Islami F, Moreira DM, Boffetta P, et al. A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol 2014; 66:1054–64.
3. Kenfield SA, Stampfer MJ, Chan JM, et al. Smoking and prostate cancer survival and recurrence. Jama 2011; 305:2548–55.
4. Giovannucci E, Liu Y, Platz EA, et al. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007; 121:1571–8.
5. Health UDo, Services H. The health consequences of smoking—50 years of progress: a report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health 2014. 17.
6. Moreira DM, Aronson WJ, Terris MK, et al. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database. Cancer 2014; 120:197–204.
7. Zu K, Giovannucci E. Smoking and aggressive prostate cancer: a review of the epidemiologic evidence. Cancer Causes Control 2009; 20:1799–810.
8. Smokeless Tobacco. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. World Health Organization, International Agency for Research on Cancer 2012; 100E:265–318.
9. Smokeless tobacco and some tobacco-specific N-nitrosamines. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. World Health Organization, International Agency for Research on Cancer 2007; 89:1–592.
10. Levy DT, Mumford EA, Cummings KM, et al. The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. Cancer Epidemiol Biomarkers Prev 2004; 13:2035–42.
11. Daniel Roth H, Roth AB, Liu X. Health risks of smoking compared to Swedish snus. Inhal Toxicol 2005; 17:741–8.
12. Gartner CE, Hall WD, Vos T, et al. Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study. Lancet 2007; 369:2010–4.
13. Foulds J, Kozlowski L. Snus—what should the public-health response be? Lancet 2007; 369:1976–8.
14. Barlow L, Westergren K, Holmberg L, et al. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol (Stockholm, Sweden) 2009; 48:27–33.
15. Fall K, Stromberg F, Rosell J, et al. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol 2008; 42:352–7.
16. Godtman R, Holmberg E, Stranne J, et al. High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm. Scand J Urol Nephrol 2011; 45:226–32.
17. Van Hemelrijck M, Wigertz A, Sandin F, et al. Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol 2013; 42:956–67.
18. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Cancer Network 2010; 8:162–200.
19. Nordenvall C, Nilsson PJ, Ye W, et al. Tobacco use and cancer survival: a cohort study of 40,230 Swedish male construction workers with incident cancer. Int J Cancer 2013; 132:155–61.
20. Roosaar A, Johansson AL, Sandborgh-Englund G, et al. Cancer and mortality among users and nonusers of snus. Int J Cancer 2008; 123:168–73.
21. Hoffmann D, Djordjevic MV, Fan J, et al. Five leading U.S. commercial brands of moist snuff in 1994: assessment of carcinogenic N-nitrosamines. J Natl Cancer Inst 1995; 87:1862–9.
22. Tobacco smoke and involuntary smoking. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. World Health Organization, International Agency for Research on Cancer 2004; 83:1–1438.
23. McAdam KG, Faizi A, Kimpton H, et al. Polycyclic aromatic hydrocarbons in US and Swedish smokeless tobacco products. Chem Central J 2013; 7:151
24. Stepanov I, Jensen J, Hatsukami D, et al. New and traditional smokeless tobacco: comparison of toxicant and carcinogen levels. Nicotine Tob Res 2008; 10:1773–82.
25. U.S. Department of Health and Human Services NCI, Centers for Disease Control and Prevention, ed. Smokeless tobacco and public health: a global perspective. vol. 14-7983. NIH Publication, Bethesda, USA, 2014.
26. Digard H, Proctor C, Kulasekaran A, et al. Determination of nicotine absorption from multiple tobacco products and nicotine gum. Nicotine Tob Res 2013; 15:255–61.
27. Cardinale A, Nastrucci C, Cesario A, et al. Nicotine: specific role in angiogenesis, proliferation and apoptosis. Crit Rev Toxicol 2012; 42:68–89.
28. Lam DC, Girard L, Ramirez R, et al. Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res 2007; 67:4638–47.
29. Lee CH, Huang CS, Chen CS, et al. Overexpression and activation of the alpha9-nicotinic receptor during tumorigenesis in human breast epithelial cells. J Natl Cancer Inst 2010; 102:1322–35.
30. Shih YL, Liu HC, Chen CS, et al. Combination treatment with luteolin and quercetin enhances antiproliferative effects in nicotine-treated MDA-MB-231 cells by down-regulating nicotinic acetylcholine receptors. J Agric Food Chem 2010; 58:235–41.
31. Chen CS, Lee CH, Hsieh CD, et al. Nicotine-induced human breast cancer cell proliferation attenuated by garcinol through down-regulation of the nicotinic receptor and cyclin D3 proteins. Breast Cancer Res Treat 2011; 125:73–87.
32. Dasgupta P, Rizwani W, Pillai S, et al. Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer 2009; 124:36–45.
33. Cooke JP, Ghebremariam YT. Endothelial nicotinic acetylcholine receptors and angiogenesis. Trends Cardiovasc Med 2008; 18:247–53.
34. Mousa S, Mousa SA. Cellular and molecular mechanisms of nicotine's pro-angiogenesis activity and its potential impact on cancer. J Cell Biochem 2006; 97:1370–8.
35. Wong HP, Yu L, Lam EK, et al. Nicotine promotes colon tumor growth and angiogenesis through beta-adrenergic activation. Toxicol Sci 2007; 97:279–87.
36. Zhang Q, Tang X, Zhang ZF, et al. Nicotine induces hypoxia-inducible factor-1alpha expression in human lung cancer cells via nicotinic acetylcholine receptor-mediated signaling pathways. Clin Cancer Res 2007; 13:4686–94.
37. Ye Y, Wang M, Hu S, et al. Hypoxia-inducible factor-1alpha C1772T polymorphism and cancer risk: a meta-analysis including 18,334 subjects. Cancer Invest 2014; 32:126–35.
38. Varkaris A, Katsiampoura AD, Araujo JC, et al. Src signaling pathways in prostate cancer. Cancer Metastasis Rev 2014; 33:595–606.
39. Shukla S, Maclennan GT, Hartman DJ, et al. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 2007; 121:1424–32.
40. Sarker D, Reid AH, Yap TA, et al. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15:4799–805.
41. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clinical Invest 2008; 118:3051–64.
42. Lawler TS, Stanfill SB, Zhang L, et al. Chemical characterization of domestic oral tobacco products: total nicotine, pH, unprotonated nicotine and tobacco-specific N-nitrosamines. Food Chem Toxicol 2013; 57:380–6.
43. Stepanov I, Jensen J, Hatsukami D, et al. Tobacco-specific nitrosamines in new tobacco products. Nicotine Tob Res 2006; 8:309–13.
44. Stepanov I, Biener L, Yershova K, et al. Monitoring tobacco-specific N-nitrosamines and nicotine in novel smokeless tobacco products: findings from round II of the new product watch. Nicotine Tob Res 2014; 16:1070–8.
45. Xue J, Yang S, Seng S. Mechanisms of Cancer Induction by Tobacco-Specific NNK and NNN. Cancers 2014; 6:1138–56.
46. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003; 3:733–44.
47. Takahashi H, Ogata H, Nishigaki R, et al. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell 2010; 17:89–97.
48. World Cancer Research Fund International/American Institute for Cancer Research Continuous Update Project Report: Diet, Nutrition, Physical Activity, and Prostate Cancer. 2014. Available at: www.wcrf.org/sites/default/files/Prostate-Cancer-2014-Report.pdf
49. Britton J. Should doctors advocate snus and other nicotine replacements? Yes. BMJ 2008; 336:358
50. Rogers JD, Biener L, Clark PI. Test marketing of new smokeless tobacco products in four U.S. cities. Nicotine Tob Res 2010; 12:69–72.
51. Popova L, Ling PM. Alternative tobacco product use and smoking cessation: a national study. Am J Publ Health 2013; 103:923–30.
52. Silver SpringMDZeller, Mitchell (Director, Center for Tobacco Products,). Letter to: Martin L. Holton III (R.J. Reynolds Tobacco Company, Winston-SalemNC). 2015 May 11. 12 p.
53. Czoli CD, Hammond D, White CM. Electronic cigarettes in Canada: prevalence of use and perceptions among youth and young adults. Can J Publ Health 2014; 105:e97–e102.
54. McMillen RC, Gottlieb MA, Shaefer RM, Winickoff JP, Klein JD. Trends in Electronic Cigarette Use Among U.S. Adults: Use is Increasing in Both Smokers and Nonsmokers. Nicotine Tob Res 2015; 17:1195–202.
55. Brown J, West R, Beard E, et al. Prevalence and characteristics of e-cigarette users in Great Britain: findings from a general population survey of smokers. Addict Behav 2014; 39:1120–5.
56. Lee S, Grana RA, Glantz SA. Electronic cigarette use among Korean adolescents: a cross-sectional study of market penetration, dual use, and relationship to quit attempts and former smoking. J Adolesc Health 2014; 54:684–90.
57. Singh TA, R.A.; Corey, C.G.; et al. Tobacco Use Among Middle and High School Students—United States, 2011–2015. MMWR Morb Mortal Wkly Rep 2016;65: 361–7.
58. Schoenborn CAG, RM. Electronic cigarette use among adults: United States, 2014. NCHS Data Brief 2015; 217:
59. Leventhal AM, Strong DR, Kirkpatrick MG, Unger JB, Sussman S, Riggs NR, Stone MD, Khoddam R, Samet JM, Audrain-McGovern J. Association of electronic cigarette use with initiation of combustible tobacco product smoking in early adolescence. Jama 2015; 314:700–7.
60. Tan AS, Bigman CA. E-cigarette awareness and perceived harmfulness: prevalence and associations with smoking-cessation outcomes. Am J Prev Med 2014; 47:141–9.
61. Grana RA, Ling PM. “Smoking revolution”: a content analysis of electronic cigarette retail websites. Am J Prev Med 2014; 46:395–403.
62. Callahan-Lyon P. Electronic cigarettes: human health effects. Tobacco Control 2014; 23 Suppl 2:ii36–40.
63. Goniewicz ML, Knysak J, Gawron M, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tobacco Control 2014; 23:133–9.